Rate of correctly identified patients (those who developed VTE) using 2 different risk models (Khorana or Vienna model) for patients with a Khorana or a Vienna score of ≥3
| Study . | Risk model . | Patient number . | N′/N″ . | Rate (%) . |
|---|---|---|---|---|
| Protecht93,94 | Khorana6 | 381 | 5/15 | 33 |
| Save-Onco93,94 | Khorana6 | 1583 | 15/54 | 28 |
| CATS19 | Khorana6 | 819 | 16/61 | 26 |
| CATS19 | Vienna19 | 819 | 33/61 | 54 |
| Study . | Risk model . | Patient number . | N′/N″ . | Rate (%) . |
|---|---|---|---|---|
| Protecht93,94 | Khorana6 | 381 | 5/15 | 33 |
| Save-Onco93,94 | Khorana6 | 1583 | 15/54 | 28 |
| CATS19 | Khorana6 | 819 | 16/61 | 26 |
| CATS19 | Vienna19 | 819 | 33/61 | 54 |
Only patients without thrombosis-prophylaxis were included in this analysis. N′, number of patients with score ≥3; N″, number of all patients with VTE.